368 related articles for article (PubMed ID: 21502559)
1. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.
Lemma GL; Lee JW; Aisner SC; Langer CJ; Tester WJ; Johnson DH; Loehrer PJ
J Clin Oncol; 2011 May; 29(15):2060-5. PubMed ID: 21502559
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.
Hirai F; Yamanaka T; Taguchi K; Daga H; Ono A; Tanaka K; Kogure Y; Shimizu J; Kimura T; Fukuoka J; Iwamoto Y; Sasaki H; Takeda K; Seto T; Ichinose Y; Nakagawa K; Nakanishi Y;
Ann Oncol; 2015 Feb; 26(2):363-8. PubMed ID: 25403584
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma.
Igawa S; Murakami H; Takahashi T; Nakamura Y; Tsuya A; Naito T; Kaira K; Ono A; Shukuya T; Tamiya A; Endo M; Yamamoto N
Lung Cancer; 2010 Feb; 67(2):194-7. PubMed ID: 19409644
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.
Inoue A; Sugawara S; Harada M; Kobayashi K; Kozuki T; Kuyama S; Maemondo M; Asahina H; Hisamoto A; Nakagawa T; Hotta K; Nukiwa T
J Thorac Oncol; 2014 Dec; 9(12):1805-9. PubMed ID: 25393793
[TBL] [Abstract][Full Text] [Related]
5. RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.
Imbimbo M; Vitali M; Fabbri A; Ottaviano M; Pasello G; Petrini I; Palmieri G; Berardi R; Zucali P; Ganzinelli M; Marabese M; Broggini M; Marino M; Trama A; Rulli E; Hollander L; Pruneri G; Torri V; Garassino MC
Clin Lung Cancer; 2018 Sep; 19(5):e811-e814. PubMed ID: 30033090
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors.
Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Ahn JS; Park K; Moon SH; Ahn MJ
J Thorac Oncol; 2015 Dec; 10(12):1800-6. PubMed ID: 26484631
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature.
Watanabe K; Shinkai M; Goto H; Yoshikawa S; Yamaguchi N; Hara Y; Shinoda M; Moriyama Y; Rubin BK; Ishigatsubo Y; Kaneko T
Tumori; 2013; 99(4):e172-6. PubMed ID: 24326856
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors.
Wang CL; Gao LT; Lyu CX; Zhang Q; Zeng WQ; Fang WT; Zhu L; Fu XL
Med Oncol; 2022 Jan; 39(2):25. PubMed ID: 34982283
[TBL] [Abstract][Full Text] [Related]
9. Advanced thymic cancer treated with carboplatin and paclitaxel in a patient undergoing hemodialysis.
Miura S; Kagamu H; Sakai T; Nozaki K; Asakawa K; Moro H; Okajima M; Watanabe S; Yamamoto S; Iino N; Goto S; Kazama JJ; Yoshizawa H; Narita I
Intern Med; 2015; 54(1):55-8. PubMed ID: 25742894
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer.
Furugen M; Sekine I; Tsuta K; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
Jpn J Clin Oncol; 2011 Aug; 41(8):1013-6. PubMed ID: 21742653
[TBL] [Abstract][Full Text] [Related]
11. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Asao T; Shukuya T; Mimori T; Goto Y; Tanaka H; Takayama K; Tsubata Y; Tachihara M; Suzuki T; Kaira K; Ko R; Zenke Y; Akamatsu H; Tanizaki J; Ikeda S; Sugawara S; Mizutani H; Mori K; Takahashi K
Clin Lung Cancer; 2023 Nov; 24(7):e247-e253. PubMed ID: 37316381
[TBL] [Abstract][Full Text] [Related]
12. Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas.
Okuma Y; Nomura S; Sakakibara-Konishi J; Tsukita Y; Murakami S; Hosomi Y; Tambo Y; Kogure Y; Yoshioka H; Tamiya M; Ninomiya K; Iwama E
Clin Lung Cancer; 2024 Jun; 25(4):389-394. PubMed ID: 38413246
[TBL] [Abstract][Full Text] [Related]
13. Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma.
Manaka H; Igawa S; Yamamoto M; Oguri A; Manabe H; Kasajima M; Kusuhara S; Hosotani S; Nakahara Y; Sato T; Fukui T; Hisashi M; Sasaki J; Naoki K
Invest New Drugs; 2023 Feb; 41(1):115-121. PubMed ID: 36633784
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.
Tsukita Y; Inoue A; Sugawara S; Kuyama S; Nakagawa T; Harada D; Tanaka H; Watanabe K; Mori Y; Harada T; Hino T; Fujii M; Ichinose M
Lung Cancer; 2020 Jan; 139():89-93. PubMed ID: 31751805
[TBL] [Abstract][Full Text] [Related]
15. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
[TBL] [Abstract][Full Text] [Related]
16. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
Gubens MA; Burns M; Perkins SM; Pedro-Salcedo MS; Althouse SK; Loehrer PJ; Wakelee HA
Lung Cancer; 2015 Jul; 89(1):57-60. PubMed ID: 26009269
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA
Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
[TBL] [Abstract][Full Text] [Related]
20. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
Loehrer PJ; Jiroutek M; Aisner S; Aisner J; Green M; Thomas CR; Livingston R; Johnson DH
Cancer; 2001 Jun; 91(11):2010-5. PubMed ID: 11391579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]